Global GLP-1 Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global GLP-1 Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
GLP-1 Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global GLP-1 Drug market is projected to reach US$ 99940 million in 2029, increasing from US$ 20430 million in 2022, with the CAGR of 25.7% during the period of 2024 to 2029. Demand from Obesity and Type 2 Diabetes (T2DM) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for GLP-1 Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, GLP-1 Drug key manufacturers include Eli Lilly, AstraZeneca, Sanofi, Pfizer Inc, Novo Nordisk, Boehringer Ingelheim, GlaxoSmithKline (GSK), East China Pharmaceutical Co., Ltd. and Gan & Lee Pharmaceuticals, etc. Eli Lilly, AstraZeneca, Sanofi are top 3 players and held % sales share in total in 2022.
GLP-1 Drug can be divided into Short-acting GLP-1 Drug and Long-acting GLP-1 Drug, etc. Short-acting GLP-1 Drug is the mainstream product in the market, accounting for % sales share globally in 2022.
GLP-1 Drug is widely used in various fields, such as Obesity, Type 2 Diabetes (T2DM), Cardiovascular and Cerebrovascular Diseases (CVD) and Non-alcoholic Steatohepatitis (NASH), etc. Obesity provides greatest supports to the GLP-1 Drug industry development. In 2022, global % sales of GLP-1 Drug went into Obesity filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Eli Lilly
AstraZeneca
Sanofi
Pfizer Inc
Novo Nordisk
Boehringer Ingelheim
GlaxoSmithKline (GSK)
East China Pharmaceutical Co., Ltd.
Gan & Lee Pharmaceuticals
Tonghua Dongbao
Shanghai Renhui Biopharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Segment by Type
Short-acting GLP-1 Drug
Long-acting GLP-1 Drug
Obesity
Type 2 Diabetes (T2DM)
Cardiovascular and Cerebrovascular Diseases (CVD)
Non-alcoholic Steatohepatitis (NASH)
Alzheimer's Disease (AD)
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the GLP-1 Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of GLP-1 Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the GLP-1 Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of GLP-1 Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, GLP-1 Drug introduction, etc. GLP-1 Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of GLP-1 Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for GLP-1 Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, GLP-1 Drug key manufacturers include Eli Lilly, AstraZeneca, Sanofi, Pfizer Inc, Novo Nordisk, Boehringer Ingelheim, GlaxoSmithKline (GSK), East China Pharmaceutical Co., Ltd. and Gan & Lee Pharmaceuticals, etc. Eli Lilly, AstraZeneca, Sanofi are top 3 players and held % sales share in total in 2022.
GLP-1 Drug can be divided into Short-acting GLP-1 Drug and Long-acting GLP-1 Drug, etc. Short-acting GLP-1 Drug is the mainstream product in the market, accounting for % sales share globally in 2022.
GLP-1 Drug is widely used in various fields, such as Obesity, Type 2 Diabetes (T2DM), Cardiovascular and Cerebrovascular Diseases (CVD) and Non-alcoholic Steatohepatitis (NASH), etc. Obesity provides greatest supports to the GLP-1 Drug industry development. In 2022, global % sales of GLP-1 Drug went into Obesity filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Eli Lilly
AstraZeneca
Sanofi
Pfizer Inc
Novo Nordisk
Boehringer Ingelheim
GlaxoSmithKline (GSK)
East China Pharmaceutical Co., Ltd.
Gan & Lee Pharmaceuticals
Tonghua Dongbao
Shanghai Renhui Biopharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Segment by Type
Short-acting GLP-1 Drug
Long-acting GLP-1 Drug
Segment by Application
Obesity
Type 2 Diabetes (T2DM)
Cardiovascular and Cerebrovascular Diseases (CVD)
Non-alcoholic Steatohepatitis (NASH)
Alzheimer's Disease (AD)
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the GLP-1 Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of GLP-1 Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the GLP-1 Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of GLP-1 Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, GLP-1 Drug introduction, etc. GLP-1 Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of GLP-1 Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices